High Fidelity Drug Repurposing, Molecular Profiling, and Cell Reprogramming
Abstract
To provide successful immediate-term treatment of PCa, and to prolong or prevent the need for androgen deprivation therapy and its lethal corollary, castrate resistant prostate cancer. We will integrate two paradigm-shifting Georgetown-Lombardi technologies (TMFS/network pharmacology and CRCs) to discover and test repurposed drugs that target PCa on an individual patient basis. Objective 1: We will enrich the FDA-approved drug database to include world-wide approved and experimental drugs and add new target structures as needed. Objective 2: TMFS will be applied to the molecular profiles derived from a series of pten mutant tumors from engineered mice and predicted drugs will be tested on conditionally reprogrammed cultures of these cells in vitro as well as in vivo as allografts. Objective 3: We will also complete the characterization of 10 human normal and prostate cancer CRC lines by Illumina bead array and RNAseq. Objective 4: These datasets will be interrogated for potential targets and repurposable drugs identified using TMFS. The drugs will be tested on prostate cells growth in vitro to calculate the LD50 in preparation for future studies in vivo.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 2016
- Accession Number
- AD1034083
Entities
People
- Chris Albanese
Organizations
- Georgetown University